LeMaitre to Participate at Upcoming Investor Conferences in March

LeMaitre Vascular, Inc. (Nasdaq: LMAT), a leading provider of medical devices and services for peripheral vascular disease, announced participation in five significant investor conferences throughout March 2026. These conferences offer a platform for the company’s management team to engage with investors and discuss its product offerings, market position, and growth prospects.

The schedule kicks off with the Leerink Partners Global Healthcare Conference in Miami on March 10, where LeMaitre's management will present at 1:00 PM EDT. The following day, the Citizens Life Sciences Conference will feature LeMaitre at 1:40 PM EDT, once again in Miami. Following that, the Barclays Annual Global Healthcare Conference on March 12 will include opportunities for one-on-one meetings with management, providing investors with tailored insights.

On March 17, the KeyBanc Capital Markets Healthcare Forum will see LeMaitre hosting a virtual presentation at 3:45 PM EDT. The firm concludes its conference participation with the 38th Annual ROTH Conference from March 22-24, also engaging in one-on-one meetings and potentially participating in discussions or presentations.

LeMaitre specializes in developing, manufacturing, and marketing vascular devices used by surgeons to treat peripheral vascular disease, affecting over 200 million individuals worldwide. Their extensive range of offerings, including both disposable and implantable devices, positions them well within the medical device sector. For further information about their products and services, interested parties are encouraged to visit their website at www.lemaitre.com.

For inquiries, Greg Manker, Director of Business Development & Investor Relations at LeMaitre, can be contacted via phone at (781) 362-1260 or email at gmanker@lemaitre.com.

LeMaitre Vascular, Inc. (Nasdaq: LMAT) is poised to capture investor interest with its participation in five key investor conferences this March, presenting a strategic opportunity for current and potential shareholders. These engagements provide LeMaitre with a platform to showcase its innovative products and solidify its position as a leading provider of peripheral vascular solutions amidst a market that serves over 200 million individuals globally.

Investors should closely monitor LeMaitre's presentations, especially during the Leerink Partners Global Healthcare Conference and the Barclays Annual Global Healthcare Conference, where management will convey the company's strategic direction and growth potential. The March 10 and March 12 sessions, respectively, are particularly important as they may offer valuable insights into ongoing product development, market expansion, and competitive positioning.

The significance of participating in multiple conferences underscores LeMaitre's commitment to maintaining transparent communication with investors and analysts. Notably, the focus on one-on-one meetings during the KeyBanc Capital Markets Healthcare Forum and the ROTH Conference facilitates deeper, more personalized engagement with key stakeholders, allowing for a nuanced discussion surrounding financial performance and growth strategies.

From a market perspective, LeMaitre’s focus on the growing peripheral vascular treatments sector is promising, especially considering the increasing prevalence of vascular diseases globally. As investors evaluate potential opportunities, the company’s ability to navigate regulatory environments and drive innovation will be critical to sustaining long-term growth.

In conclusion, LeMaitre's active engagement in these investor conferences is an encouraging signal, indicating the management's confidence in the company's future trajectory. As the firm articulates its value proposition and growth strategies, now may be an opportune time for investors to assess their positions in the stock before these conferences transpire and market sentiment shifts.